silencer

**Definition:** Silencers are short DNA sequences (cis-acting elements) that, when bound by specific transcription repressors (trans-acting factors), reduce transcription of a target gene. They are the counterpart to enhancers, which increase transcription.

**Key features:** - Can be located upstream, downstream, or within introns of the gene, often far from the promoter. - Function in an orientation-independent manner, like enhancers. - Bound by repressor proteins, which may block activator binding, interfere with the general transcription factors or RNA polymerase II assembly at the promoter, or recruit corepressors such as histone deacetylases (HDACs) and chromatin-condensing complexes.

**Mechanisms of silencing:** 1. Competitive binding: a repressor occupies a site that overlaps an activator's binding site. 2. Quenching: a repressor binds an activator and blocks its activation domain. 3. Direct inhibition of the basal transcription machinery. 4. Chromatin remodeling: HDAC recruitment leads to histone deacetylation, then condensed heterochromatin and a transcriptionally silent state. DNA methylation of CpG islands also contributes to long-term silencing.

**Comparison of regulatory elements:** - Promoter: located just upstream of the gene (TATA box about -25, CAAT box about -75, GC box). Binds general transcription factors and RNA polymerase II. Sets the basal transcription level. - Enhancer: cis-acting, binds activators, and increases transcription. - Silencer: cis-acting, binds repressors, and decreases transcription. - Insulator: blocks enhancer-promoter interaction or prevents spread of heterochromatin.

**Clinical significance and associations:** - Mutations in silencer elements or their repressors can cause inappropriate gene expression. Examples include NRSF/REST, a repressor that silences neuronal genes in non-neuronal cells, and aberrant silencing of tumor suppressor genes in cancer. - Epigenetic silencing: hypermethylation of tumor suppressor promoters (e.g., BRCA1, MLH1, p16/CDKN2A) causes loss of expression. Hypomethylating agents (azacitidine, decitabine) and HDAC inhibitors (vorinostat) are used therapeutically in myelodysplastic syndromes and T-cell lymphoma. - Genomic imprinting and X-inactivation (XIST) are examples of stable gene silencing.

**Do not confuse with:** - RNA interference (siRNA/miRNA), which is post-transcriptional "gene silencing" and is mechanistically distinct from DNA silencer elements. - Repressor/operator: the prokaryotic analog is the operator bound by a repressor (e.g., lac operon with lac repressor).

**Board pearl:** Enhancers and silencers are cis-acting DNA elements. The proteins that bind them (activators and repressors) are trans-acting factors.